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10.Identifying coronary artery disease (CAD) in atrial fibrillation (AF) patients improves risk
stratification and defines clinical management. However, the value of screening for sub-
clinical CAD with cardiac CT in AF patients is unknown. Between 2011 and 2015, 94 con-
secutive patients without known or suspected CAD (66 (57−73) years, 68% male), who
were referred for AF evaluation, underwent a noncontrast-enhanced coronary calcium
scan and a coronary computed tomography angiography (CCTA) at our center. We retro-
spectively evaluated the coronary calcium score, the prevalence of obstructive CAD
(≥50% stenosis) determined by CCTA, compared clinical management and 5-year out-
come in patients with and without obstructive CAD on CCTA, and examined the potential
impact of a coronary calcium score and obstructive CAD on CCTA as a manifestation of
vascular disease on the CHA2Ds2VASc score and for the cardiovascular risk stratification
of AF patients. The median coronary calcium score was 57 (0−275) and 24 patients (26%)
had obstructive CAD on CCTA. At baseline, patients with obstructive CAD more often
used statins than those without obstructive CAD (54% vs 26%, p = 0.011). After a median
clinical follow-up of 2.4 (0.5−4.5) years, patients with obstructive CAD more frequently
used oral anticoagulant and/or antiplatelet drugs, statins, angiotensin-II-receptor blockers
and/or angiotensin-converting-enzyme inhibitors, and less often used class I antiarrhyth-
mic drugs than patients without obstructive CAD (all p <0.050). After a median follow-up
of 5.7 (4.8−6.8) years, mortality was higher in patients with obstructive CAD than in those
without obstructive CAD (29% vs 11%, log-rank test: p = 0.034). Implementation of a cor-
onary calcium score and/or obstructive CAD on CCTA elevated the CHA2Ds2VASc score
and cardiovascular risk stratification in 42 patients (p <0.001) and 47 patients (p = 0.006),
respectively. In conclusion, we observed a high prevalence of obstructive CAD
on CCTA in AF patients without known or suspected CAD. AF patients with obstructive
CAD were managed differently and had a worse prognosis than those without
obstructive CAD. Cardiac CT could enhance cardiovascular risk stratification of AF
patients. © 2020 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1016/j.amjcard.2020.03.050Atrial fibrillation (AF) is the most common arrhythmia,
with gradually increasing prevalence worldwide.1 The mor-
tality of patients with AF is nearly twice higher compared
with individuals without AF.2 Partially, this can be
explained by the high prevalence of concomitant diseases
such as coronary artery disease (CAD), heart failure, and
valvular heart disease.3 Identification and management of
these conditions have been recommended by international
guidelines to improve AF burden and outcome.4 Previousmyocardial infarction increases the risk for thromboembolic
and coronary events of AF patients, and is incorporated in
the risk stratification algorithm for stroke (eg, CHA2Ds2-
VASc score) and cardiovascular events (eg, SCORE).5,6
However, early detection of CAD in AF patients has shown
to be prognostic valuable with a substantial potential impact
on clinical management, including initiation of anticoagula-
tion therapy, statins, and the choice of antiarrhythmic
drugs.4,7−10 Coronary computed tomography angiography
(CCTA) has emerged as a valuable diagnostic tool to evalu-
ate CAD in patients with stable chest pain.11 In this study,
we investigated the prevalence of CAD by CCTA in AF
patients without known or suspected CAD, compared clin-
ical management and outcome in AF patients with and
without obstructive CAD, and examined the potential
value of a noncontrast-enhanced calcium scan and CCTA
on the stroke and cardiovascular risk stratification in AF
patients of whom the majority were referred by their pri-
mary physicians.
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From January 2011 to January 2015, a total of 94 conse-
cutive patients without known or suspected CAD were
referred to a dedicated AF outpatient clinic at our center
and underwent a cardiac CT as part of routine clinical man-
agement. The large majority of patients were referred by
primary or internal medicine physicians with recently diag-
nosed AF. The clinical evaluation consisted of a compre-
hensive clinical examination, blood tests, a transthoracic
echocardiogram, and a noncontrast-enhanced coronary cal-
cium scan with a CCTA to identify subclinical CAD.
CCTA exclusion criteria were pregnancy, renal failure with
a glomerular filtration rate <60 ml/min/1.73 m2, and known
allergy to contrast agents. The absence of known or sus-
pected CAD was defined as the absence of a history of
ischemic heart disease, heart failure, severe valvular dis-
ease, electrocardiogram abnormalities (ie, pathologic q
waves), or angina pectoris. AF was defined according to the
European guidelines for management of AF.4 The study
was conducted in accordance with Declaration of Helsinki
and with research ethics committee approval. The need for
informed consent was waved on the basis of the retrospec-
tive nature of the study.
All CT scans were performed on second- (96%) or third-
generation (4%) dual-source CT scanners (Somatom Defi-
nition Flash or Force, Siemens Healthineers, Forchheim,
Germany). Ninety-three out of 94 patients underwent a non-
contrast-enhanced scan to determine a coronary calcium
score according to the Agatston method.12 Multi-Ethnic
Study of Atherosclerosis percentiles were calculated
according to the coronary calcium score distribution by
age, gender, and ethnicity.13 CCTA was performed in all
patients using a retrospectively electrocardiogram-gated
spiral (48%), prospectively electrocardiogram-triggered
axial (50%), or prospectively electrocardiogram-triggered
high-pitch spiral (2%) scan mode depending on the heart
rate and heart rate variability. The heart rhythm during
CCTA in those who were scanned in a retrospectively elec-
trocardiogram-gated spiral scan mode was sinus rhythm in
5 patients (11%), AF or other arrhythmia in 29 patients
(64%), and was not reported in 11 patients (24%). The heart
rhythm during CCTA in those who were scanned with a
prospectively electrocardiogram-triggered axial or high-
pitch spiral scan mode was sinus rhythm in 37 patients
(76%), AF and other arrhythmia in 2 patients (4%), and was
not reported in 10 patients (20%). The image quality was
scored based on a 4-point Likert score and was excellent in
48 patients (51%), good in 36 patients (38%), impaired in
10 patients (11%), and nondiagnostic in none of the
patients. The median radiation dose of the entire cardiac
CT examination was 7.3 (4.2−12.1) mSv using a conver-
sion coefficient of 0.014mSv/ (mGy*cm); a median radia-
tion dose of 11.4 (7.7−17.2) mSv for those who were
scanned with a retrospectively electrocardiogram-gated spi-
ral scan mode and a median radiation dose of 4.5 (2.8−7.0)
mSv for those who were scanned with a prospective electro-
cardiogram-gated axial or high-pitch scan mode. Patients
received sublingual nitroglycerin before CCTA and beta-
blockers if indicated (heart rate >65/min) and clinically
safe. The cardiac CT scans were interpreted as part ofroutine clinical care by radiologists with extensive experi-
ence in cardiac imaging, in accordance with international
guidelines.14 Obstructive CAD was defined as the presence
of at least 1 stenosis ≥50%.
Medication use and therapeutic procedures were col-
lected from medical records at the time of the first clinical
visit when also the cardiac CT was performed and at the
time of the last known clinical outpatient visit at our center.
All-cause mortality was determined at time of the data col-
lection using the Dutch National Mortality Registry. The
medication use, the number of previous cardiac interven-
tions, and deaths were compared between AF patients with
and without obstructive CAD on CCTA.
The CHA2Ds2VASc (Congestive heart failure, Hyper-
tension, Age 65−74 or ≥75 years, diabetes mellitus, stroke
or systemic embolism, vascular disease [peripheral arterial
disease, previous myocardial infarction or aortic plaque],
and gender category [ie, female gender]) score was calcu-
lated in each patient at the first clinical visit. Based on the
published observations that a calcium score >100 and
obstructive CAD (≥50% stenosis) predict stroke,9,15,16 we
tested the potential impact of a calcium score and CCTA
findings on the CHA2Ds2VASc score by considering a cal-
cium score >100 and/or the presence of ≥50% stenosis on
CCTA as a manifestation of vascular disease which adds 1
point to the CHA2Ds2VASc score. The CHA2Ds2VASc
score was re-calculated first with the calcium score alone
and second with both the calcium score and CCTA findings
to investigate the potential value of the calcium score alone
and the additional value of CCTA findings on the CHA2Ds2-
VASc score. We determined the number of patients with an
increase in CHA2Ds2VASc score and who would potentially
be reclassified to oral anticoagulation for stroke prevention
with the findings of the noncontrast-enhanced scan alone and
with the findings of both the noncontrast-enhanced scan and
the CCTA.
To investigate the potential clinical impact of the cal-
cium score and CCTA on the cardiovascular risk stratifica-
tion of AF patients and the utilization of statin therapy, we
reassessed the cardiovascular risk stratification according to
the European guidelines of cardiovascular disease preven-
tion in clinical practice with (1) a calcium score alone and
with (2) both a calcium score and CCTA findings.7 A
reclassification rate was calculated as a proportion of
patients who were reclassified after the implementation of
the coronary calcium score and CCTA findings. In accor-
dance to European guidelines patients were classified as
very high-risk, high-risk, moderate-risk, and low-risk
(Table 1). Subsequently, patients were reassessed based on
the clinical characteristics and coronary calcium score. A
coronary calcium score of 0 reclassified the patient to a
lower risk category. Patients with a calcium score of ≥300
or ≥75th percentile were reclassified to a higher risk cate-
gory. Finally, patients were assessed based on the clinical
characteristics, coronary calcium score, and CCTA find-
ings. Obstructive CAD (≥50% stenosis) on CCTA reclassi-
fied patients to the very high-risk category.
Absolute variables are represented as totals with percen-
tages and continuous variables as means § standard devia-
tions or median with 25th−75th percentiles. Chi-square
test, Fisher’s exact test, and McNemar’s test were used to
Table 1
Cardiovascular risk categories: Anyone in each category
Very high-risk - A prior stroke, aortic aneurysm, peripheral artery disease, or chronic kidney disease with a globular filtration rate
<30 mL/min/1.73 m2.
- Diabetes mellitus with a major cardiovascular risk factor (hypertension, hypercholesterolemia or smoking).
- A calculated SCORE (10-year risk of fatal cardiovascular disease) of ≥10%.
High-risk - Diabetes mellitus without major risk factors.
- Chronic kidney disease with a globular filtration rates 30−59 mL/min/1.73m2.
- A calculated SCORE of ≥5% and <10%.
Moderate-risk Defined as a calculated SCORE of ≥1 and <5%
Low-risk Defined as a calculated SCORE of <1%
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signed-rank test was used to test the differences in continu-
ous variables. The survival probability was estimated by
Kaplan-Meier survival analysis and log-rank test was used
to compare the survival distribution of AF patients with and
without obstructive CAD on CCTA. A 2-sided p value of
<0.05 was considered statistically significant. StatisticalTable 2
Baseline characteristics (N = 94)
Age (years) 66 (57−73)
Men 64 (68%)
Symptomatic atrial fibrillation* 51 (54%)
Atrial fibrillation type
Paroxysmal 65 (69%)
Persistent 18 (19%)
Permanent 11 (12%)
Ablation in history 1 (1%)
CHA2Ds2VASc scorey 2 (1−3)
HAS-BLED scorez 1 (0−1)
Body mass index ≥30 kg/m2 24 (26%)
Hypertensionx 44 (47%)
Hypercholesterolemiax 27 (28%)
Diabetes mellitusx 13 (14%)
Prior stroke 13 (14%)
Peripheral artery disease or aortic aneurysms 4 (4%)
Chronic kidney disease|| 2 (2%)
Thyroid dysfunction# 7 (7%)
Smoking (current and previous) 44 (47%)
Alcohol ≥2 units/day 23 (24%)
Transthoracic echocardiogram
Left ventricular ejection fraction <45% 10 (11%)
Abnormal left atrial diameter** 46 (49%)
Valvular heart diseaseyy 5 (5%)
Continuous data are presented as median (25th to 75th percentile).Cate-
gorical data are presented as absolute numbers and percentage (%).
*Defined as an EHRA score ≥2: 1 = no symptoms, 2 = mild symptoms,
3 = severe symptoms, 4 = disabling symptoms.
yCHA2Ds2VASc score: 1 point for congestive heart failure, hyperten-
sion, age 65 to 74, diabetes mellitus, vascular disease, and female gender,
and 2 points for previous stroke or thromboembolism and age ≥75.
zHAS-BLED score: 1 point for hypertension, abnormal renal and/or liver
function, stroke, bleeding history or predisposition to bleeding, labile inter-
national normalized ratio, age >65 years, medication usage predisposing
bleeding, severe alcohol use.
xBased on medication use.
|| Based on eGFR <60 ml/min/1.73m2.
# Based on history of thyroid dysfunction or thyroid medication.
**Defined as left atrial diameter >38 mm for females and >40 mm for
males.
yyDefined as moderate to severe valvular heart disease (9 missing values).analyses were performed using SPSS (version 25, IBM
Corp, Armonk, NY).Results
The study population consisted of 94 consecutive
patients (66 [57−73] years, 68% male) with predominately
paroxysmal AF (69%) and a median CHA2Ds2VASc score
of 2 (1−3; Table 2). Twenty-two patients had a CHA2Ds2-
VASCs of 0 and 20 patients (4 females and 16 males) had a
CHA2Ds2VASCs of 1. Thirteen patients (14%) had diabe-
tes mellitus, 13 patients (14%) had a previous history of
stroke, 4 patients (4%) had peripheral artery disease (n = 2)
or an aortic aneurysm (n = 2), and 2 patients (2%) had
chronic kidney disease. The transthoracic echocardiogram
showed an ejection fraction <45% in 10 patients (11%) and
moderate to severe valvular heart disease in 5 patients
(5%).
The median Agatston score was 275 (57−1564), and 31
patients (33%) had a score of 0 indicating no detectable cor-
onary calcium (Table 3). The calcium score was >100 in 40
patients (42%) and ≥300 and/or Multi-Ethnic Study of Ath-
erosclerosis percentile ≥75 in 38 patients (40%). CCTA
showed obstructive CAD (≥50% stenosis) in 24 patients
(26%), including 12 patients (13%) with high-risk CAD
(left main stenosis, proximal left anterior descending steno-
sis or 3-vessel disease [all ≥50% stenosis]).Table 3
Cardiac computed tomography findings (N = 94)
Coronary calcium scan
Agatston calcium score* 57 (0−275)
0 31 (33%)
1−100 22 (23%)
101−400 19 (20%)
≥400 21 (22%)
Coronary computed tomography angiography
Coronary artery diseasey
None 26 (28%)
None obstructive 44 (47%)
Low-risk obstructive 12 (13%)
High-risk obstructivez 12 (13%)
Categorical data are presented as absolute numbers and percentage (%).
* 1 missing value.
yObstructive coronary artery disease defined as a stenosis ≥50%.
zHigh-risk coronary artery disease defined as 3-vessel disease, obstruc-
tive stenosis in left main or obstructive stenosis in left anterior descending.
Figure 1. The medication use and therapeutic interventions of AF patients with (continuous line) and without (dashed line) CAD at the time of the first visit
with cardiac CT (baseline) and at the last outpatient clinic visit (follow-up). Chi-square test and Fisher’s exact test were used to test the differences between
obstructive and nonobstructive AF patients with *p <0.05. AF = atrial fibrillation; CAD = coronary obstructive CAD; CT = computed tomography.
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and the last outpatient clinic visit was 2.4 (0.5−4.5) years. At
the first visit, patients with obstructive CAD already used sta-
tins more often than patients without obstructive CAD (54%
vs 26%, respectively, p = 0.011; Figure 1). At the last outpa-
tient clinic visit, patients with obstructive CAD more fre-
quently used oral anticoagulant and/or antiplatelet drugs,
statins, angiotensin-II-receptor blockers and/or angiotensin-
converting-enzyme inhibitors, and less often used class I anti-
arrhythmic drugs than patients without obstructive CAD (all
p <0.050).Patients with obstructive CAD (29%) more often
underwent revascularization than those without obstructive
CAD (3%, p <0.001). After a median follow-up of 5.7 (4.8
−6.9) years, the all-cause mortality in AF patients with and
without obstructive CAD was 29% versus 11% (p = 0.055),
respectively. The log-rank test for pairwise comparisons of
the Kaplan-Meier survival curves showed a significantFigure 2. Kaplan-Meier survival curves of AF patients with obstructive (continuo
comparisons of the survival curves was performed to compare both groups (p = 0.0different between AF patients with and without obstructive
CAD (p = 0.034; Figure 2).
If a coronary calcium score >100 would be considered
as manifestation of vascular disease (in addition to myocar-
dial infarction, peripheral artery disease, aortic plaque), the
CHA2Ds2VASc score increased in 38 patients (40%, p
<0.001), including in 3 patients from 0 to 1 and in 1 female
patient from 1 to 2 who would have been reclassified to oral
anticoagulant drug use (p = 0.125). The addition of obstruc-
tive CAD on CCTA would have increased the CHA2Ds2-
VASc score in an additional 4 patients (4%, p = 0.046), of
which 1 patients increased from 0 to 1 who would have
been reclassified to oral anticoagulant therapy (p = 1.000).
The risk stratification based on clinical risk factors clas-
sified 11 patients (12%) as low-risk, 34 patients (36%) as
moderate-risk, 18 patients as high-risk (19%), and 31
patients (33%) as very high-risk (Figure 3). The addition ofus line) and nonobstructive CAD (dashed line). A log-rank test for pairwise
34). AF = atrial fibrillation; CAD = coronary obstructive CAD.
Figure 3. Cardiovascular risk stratification of AF patients based on clinical patient characteristics, calcium score, CCTA findings. A reclassification rate was
calculated as a proportion of patients who were reclassified after the implementation of the coronary calcium score and CCTA findings and statistically tested
by chi-square tests. AF = atrial fibrillation; CAD = coronary artery disease; CCTA = coronary computed tomography angiography.
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(p = 0.040) of whom 24 patients were reclassified to a lower
risk classification based on a calcium of 0 and 20 patients to
a higher risk classification based on a calcium score
≥300 and/or Multi-Ethnic Study of Atherosclerosis percen-
tile ≥75. The addition of the CCTA findings reclassified
8 patients to very high-risk (reclassification rate 9%,
p = 0.018). Overall, the cardiovascular risk was reclassified
in 47 patients (50%) with calcium score and CCTA
(p = 0.006). Six out of 15 patients (40%) who did not sur-
vive would have been reclassified to a different cardiovas-
cular risk classification of which 5 patients would have
been classified to a higher cardiovascular risk classification
and 1 patient to a lower cardiovascular risk classification
(from very high-risk to high-risk).Discussion
In this study, we demonstrate a high prevalence of
obstructive CAD in AF patients without known or sus-
pected CAD as well as differences in medical management
and mortality rate in AF patients with and without obstruc-
tive CAD. Additionally, we demonstrated the potential clin-
ical implications of both calcium imaging and CCTA for
the stroke and cardiovascular risk stratification in AF
patients.
CAD is associated with the development and recurrence
of AF, the presence of AF symptoms, and an increased risk
of death.17−20 Multiple studies have shown a high preva-
lence of CAD (»30% to 40%) in AF patients based on
reported medical history, angina symptoms, and electrocar-
diogram abnormalities.18,19 Our current study shows a high
prevalence of CAD (26%) in AF patients without known or
suspected CAD and underlines the hypothesis of AF as a
marker of advanced coronary atherosclerosis. Furthermore,3-vessel, left main, and/or proximal left anterior descending
disease was identified in 13% of our study population.
However, the underlying pathophysiologic mechanism
between CAD and AF is not completely understood.
Inflammation and ischemia have been suggested to cause
atrial damage subsequently stimulating electrical and struc-
tural remodeling, resulting in AF.21 Additionally, CAD has
shown to be an independent risk factor for ischemic stroke,
which may be caused by an elevated protrombotic state in
the presence of a high atherosclerosis burden.16
Cardiac CT is an accurate technique for CAD detection
both in patients with and without AF.22,23 However, only a
few studies have addressed the clinical role of calcium
imaging and CCTA in the management of AF patients.8,24
Chaikriangkrai et al performed coronary imaging in AF
patients without known or suspected CAD and found a
higher prevalence of CAD (calcium score >0) compared
with patients in sinus rhythm.8 A calcium score >0 was
identified in 74% of the study population, which is similar
to our cohort (67%). Nucifora et al investigated the preva-
lence of CAD in AF patients using CCTA and found
obstructive CAD in 41%, significantly more than in a
matched control group without AF (27%).24 In their cohort,
more than half of the AF patients with obstructive CAD
had left main and/or proximal LAD disease. We also
observed that half of the patients with coronary obstructions
had high-risk obstructive CAD. However, the overall preva-
lence of obstructive CAD in their AF population was higher
than in our study due to a more high-risk/angina study pop-
ulation. These observations stress the potential clinical rele-
vance of subclinical CAD in AF patients and may explain
the increased risk of cardiovascular events in AF patients.25
Moreover, we show that the mortality rates in patients with
obstructive CAD are higher than in those without obstruc-
tive CAD.
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ered a risk factor in the risk stratification for stroke.4 How-
ever, recent studies have shown that CAD without clinical
manifestation of myocardial infarction independently
predicts thromboembolic events.9,16 Moreover, AF is an
independent risk factor for the development of new cardio-
vascular events, which suggests that cardiovascular risk
stratification based on clinical cardiovascular risk factors
alone may be insufficient.7,25 Both the coronary calcium
score and CCTA can improve risk stratification for stroke
and other cardiovascular events.13,15,26 Chaikriangkrai et al
evaluated the clinical implications of a calcium score in AF
patients without known or suspected CAD and identified
19% of the patients as new potential candidates for oral
anticoagulation by adding a calcium score >100 to the
CHA2DsVASc scores and 12% of the patients (calcium
score ≥300) as new potential candidates for statin therapy.8
We found a much lower prevalence of new potential candi-
dates for oral anticoagulation with calcium score (4%) and
CCTA (1%), but did find significant reclassification of car-
diovascular risk after the implementation of a calcium score
and CCTA in AF patients with known or suspected CAD.
More research is needed to prospectively demonstrate the
incremental clinical value of a coronary calcium score or
CCTA for risk stratification of AF patients and the impact
of therapeutic decision and clinical outcome.
Class I antiarrhythmic drugs are recommended for rhythm
control therapy in AF patients without structural heart dis-
ease.4 It is advised to evaluate for CAD in patients with car-
diovascular risk factors before administrating class I
antiarrhythmic drugs, considering that recurrent or chronic
ischemia can lead to impaired left ventricular conduction and
thereby cause proarrhythmic effects of class IC antiarrhyth-
mic drugs.10 For this reason, the presence of CAD has been a
contraindication for the use of class I antiarrhythmic drugs.4
In our study, none of the patients with obstructive CAD
received class I antiarrhythmic drugs. However, whether the
presence of CAD on CCTA has the same consequence as
CAD on conventional angiography requires further investiga-
tion. Furthermore, we show a high prevalence of high-risk
obstructive CAD in our study population.24 Although routine
screening in asymptomatic patients is currently not recom-
mended, early detection of CAD by CCTA may be valuable
in AF patients to identify patients who might benefit from
preventive or therapeutic therapy.27,28
This study has several limitations that should be acknowl-
edged. The retrospective, observational nature and the cohort
size do not allow drawing of causal relationships between
cardiac CT findings and clinical outcomes. Finally, the
observed radiation dose of cardiac CT was still high in this
population, which might limit the clinical use in asymptom-
atic AF patients. However, the use of more recent generation
scanners and the implementation of dose-saving algorithms
are likely to result in substantial dose reduction, without deg-
radation of image quality. Whether identification and treat-
ment of AF patients with occult coronary disease improves
clinical outcome will require further research.
In conclusion, the prevalence of obstructive CAD is high
in AF patients without known or suspected CAD. AF
patients with obstructive CAD on CCTA had a more inten-
sified medical treatment and a worse clinical outcome thanpatients without obstructive CAD. Cardiac CT could be a
valuable tool for the risk stratification of AF patients.Author Contribution
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